复荣通脉胶囊联合利拉鲁肽对2型糖尿病颈动脉内膜中层厚度的影响

Efficacy of Furong Tongmai Capsules plus liraglutide on the carotid intima-media thickness in patients with T2DM

目的 分析复荣通脉胶囊联合利拉鲁肽注射液对2型糖尿病(T2DM)患者颈动脉内膜中层厚度(CIMT)及脂代谢的影响。方法 纳入2021年3—10月河北省沧州中西医结合医院内分泌三科收治的T2DM合并颈动脉内膜增厚或斑块患者,最终共90例入组。根据用药方案的不同将患者分为复荣通脉胶囊联合利拉鲁肽组(治疗组,n=47)、利拉鲁肽组(对照组,n=43)。收集所有患者的一般临床资料、实验室检查、CIMT等指标,分析各组患者治疗前后组内、组间相关临床指标变化情况及CIMT与实验室指标的相关性。结果两组治疗前一般资料及CIMT、实验室指标比较差异无统计学意义(P> 0.05)。总体研究对象的实验室指标中,低密度脂蛋白胆固醇(LDL-C)、同型半胱氨酸(Hcy)、超敏C反应蛋白(hs-CRP)与CIMT呈正相关(P <0.05)。两组各组内治疗后CIMT、LDL-C、总胆固醇(TC)、三酰甘油(TG)、Hcy、hs-CRP与治疗前比较,指标好转,差异有统计学意义(P <0.05)。治疗组CIMT、hs-CRP治疗效果(治疗后-治疗前)与对照组治疗效果相比,差异有统计学意义(P <0.05)。结论 利拉鲁肽能够降低T2DM患者CIMT、炎症指标及同型半胱氨酸水平,改善血脂;复荣通脉胶囊有助于改善T2DM患者炎症指标、颈动脉内膜中层厚度。

Objective To analyze the efficacy of Furong Tongmai Capsules plus liraglutide injection on carotid intima-media thickness(CIMT)and lipid metabolism in patients with type 2 diabetes mellitus(T2DM).Methods A total of 90 patients with T2DM with carotid intima thickening or plaque admitted to the Department of EndocrinologyⅢat Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine from March to October 2021 were enrolled as study subjects.These patients were divided into a Furong Tongmai Capsules+liraglutide group(treatment group,n=47)and a liraglutide group(control group,n=43)according to different medication regimens.The general clinical data,laboratory test results,CIMT and other indicators of all patients were collected,and the intra-group and inter-group changes of relevant clinical indicators before and after treatment as well as the correlation between CIMT and laboratory indicators of patients were analyzed.Results There were no statistically significant differences between the two groups in general data,CIMT and laboratory indicators before treatment(P>0.05).The laboratory indicators such as low-density lipoprotein cholesterol(LDL-C),homocysteine(Hcy),and hypersensitive C-reactive protein(hs-CRP)of all patients were positively correlated with CIMT(P<0.05).The CIMT,LDL-C,total cholesterol(TC),triglyceride(TG),Hcy,and hs-CRP were improved in both groups after treatment,with statistically significant differences from those before treatment(P<0.05).There were statistically significant differences between the two groups in the treatment effects(post-treatment-pre-treatment)for CIMT and hs-CRP(P<0.05).Conclusion Liraglutide can reduce CIMT and the levels of inflammatory indicators and Hcy,and improve blood lipids in T2DM patients,while Furong Tongmai capsules can improve inflammatory indicators and CIMT in T2DM patients.